A Phase 1 Randomized, Single-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 (Fluzone + 60%W805EC) in Healthy Adult Volunteers

Trial Profile

A Phase 1 Randomized, Single-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 (Fluzone + 60%W805EC) in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2011

At a glance

  • Drugs Influenza virus vaccine; Influenza virus vaccine; NB 1008
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 05 Apr 2011 ClinicalTrials.gov record identified and integrated.
    • 12 Sep 2010 Results were presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • 11 Sep 2010 Results will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a NanoBio Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top